Comparing the Impact of Stenting vs. Medical Therapy for Intracranial Arterial Stenosis: A Systematic Review and One-stage and Two-stage Meta-Analysis of Randomized Clinical Trials.

Autor: Yeo, Joshua Y. P., Yau, Chun En, Ong, Natasha Yixuan, Teo, Yao Hao, Gopinathan, Anil, Yang, Cunli, Jing, Mingxue, Yang, Joanna J. W., Sia, Ching-Hui, Tan, Benjamin Yong Qiang, Yeo, Leonard Leong Litt
Zdroj: Clinical Neuroradiology; Jun2024, Vol. 34 Issue 2, p379-390, 12p
Abstrakt: Purpose: In the treatment of intracranial arterial stenosis (ICAS), controversies remain regarding the optimal treatment strategy. Our study aims to conduct an individual patient-level data meta-analysis of existing RCTs comparing PTAS versus best medical therapy and to identify differences in outcomes such as incidence of ischemic stroke or death. Methods: Randomised controlled trials comparing the outcomes of stenting versus best medical therapy for patients who had symptomatic ICAS of >50%. Excluded studies included case reports, case series, reviews, observational studies, letters or studies evaluating isolated angioplasty techniques without stenting. Data was extracted in accordance with PRISMA guidelines. Results: 7 studies involving 1425 participants were included. There was an increased risk in the incidence of stroke and death within the first 30 days post-procedure for patients treated with PTAS over best medical therapy (RR = 2.22 [1.28–3.86], I² = 0%). Patients who underwent stenting also had a significantly higher risk of intracranial haemorrhage (RR = 12.66 [2.41–66.45], I² = 0%) and death (RR = 5.41 [1.20–24.28], I² = 0%). Under the shared frailty model, stenting when compared to medical therapy has a HR of 1.81 (95% CI:1.25–2.6) of stroke or death across 1 year. Under the parametric Royston-Parmar model, stenting has a significant decrease in the RMST(–0.83 months; 95% CI: –1.30–0.37). Stenting continued to show worse outcomes up to the 3 year mark with a HR of 1.60 (95% CI: 1.11–2.32). Conclusions and Relevance: There is an increased risk of peri- and post-procedural stroke and death over best medical therapy in patients with symptomatic ICAS who undergo PTAS. Further work is required to refine patient selection and mitigate peri-procedural risks. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: